Lantern Pharma/$LTRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantern Pharma
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Ticker
$LTRN
Sector
Primary listing
Employees
16
Headquarters
Website
Lantern Pharma Metrics
BasicAdvanced
$50m
-
-$1.45
-
-
Price and volume
Market cap
$50m
52-week high
$5.74
52-week low
$1.11
Average daily volume
291k
Financial strength
Current ratio
1.868
Quick ratio
1.674
Total debt to equity
1.714
Profitability
EBITDA (TTM)
-16.593
Management effectiveness
Return on assets (TTM)
-73.31%
Return on equity (TTM)
-157.37%
Valuation
Price to book
12.71
Price to tangible book (TTM)
12.71
Price to free cash flow (TTM)
-2.842
Free cash flow yield (TTM)
-35.18%
Free cash flow per share (TTM)
-1.369
Growth
Earnings per share change (TTM)
-21.45%
3-year earnings per share growth (CAGR)
3.92%
Lantern Pharma News
AllArticlesVideos
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Business Wire·2 weeks ago
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Business Wire·4 weeks ago
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs